Skip to contentC
China Pharma Holdings, Inc.
C
CPHIChina Pharma Holdings, Inc. Q2 2019 · 10-Q
Revenue$2.57M$2.57M−19.0% vs Q2 2018 Net Income-$838.10K-$838.10KN/M vs Q2 2018 EPS Diluted-$0.02-$0.02N/M vs Q2 2018 Gross Profit$163,548−71.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
China Pharma Holdings, Inc. · CIK 1106644 · Engraved from SEC EDGAR
Operating Cash Flowderived$841,277N/M Free Cash Flowderived$841,605N/M Margins · derivedGross margin6.4%−11.9 pt vs Q2 2018
Operating margin-29.3%−2.1 pt vs Q2 2018
Net margin-32.6%−0.9 pt vs Q2 2018
ended Jun 30, 2019 · filed Aug 14, 2019 · 45 d after period end